Compare AbbVie Inc (ABBV) vs Avient Corporation (AVNT) Price & Performance

AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.

The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.

Avient Corporation (AVNT) trades at $38.89, up 4.23% today, reflecting positive momentum. The stock exhibits a bullish technical outlook with strong analyst support (12 Buy, 8 Hold, 0 Sell). Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $0.83 surpassing the $0.81 forecast. The company maintains solid fundamentals, including a P/E of 22.58 and net income margin of 4.81%, while recent news highlights innovation in non-PFAS barrier technology and new dielectric thermoplastics.

The outlook for AVNT is positive, driven by earnings outperformance, strategic product launches, and favorable analyst sentiment. Key opportunities include growth in 5G/6G materials and sustainable packaging solutions. Risks involve exposure to economic cycles impacting demand and competitive pressures in the specialty materials sector. Investors should weigh strong fundamentals against market volatility and execution risks.